The discovery and classification of molecular biomarkers and diagnostics is holding promise for the effective delivery of precision medicine. With advanced enabling technologies, we are now able to arm clinicians with deep molecular information for a variety of diseases – from cancer to infectious diseases, and molecular biomarkers are at the heart of this research. Moving beyond just the genome, this series will focus on the various omics layers that are influencing our understanding of disease and helping inform clinical decision making.
Join us for this unique three-part webinar series as we dive into the discovery of novel biomarkers, and the development and utilisation of molecular diagnostics in the context of precision medicine.
By registering for the first webinar in the series you will automatically gain access to the subsequent webinars. Register for the webinar series here.
Webinar 1: Enabling technologies and novel biomarker research
1st December 2021, 3pm GMT/ 4pm CET/ 10am EST
The discovery of new biomarkers holds promise for future diagnostic development which ultimately, could be used to inform clinical decision making and hopefully, influence patient outcomes. There is an array of enabling technologies that are fuelling this research, and this webinar will cover those as well as highlight success stories of discovery.
Speakers:
Why do 98% of biomarkers fail? – Christopher Peters, Clinical Senior Lecturer and Consultant Upper GI & General Surgeon, Imperial College London
Biomarker identification, selection and development – Xianyin Lai, Senior Research Scientist, Eli Lilly
Fractional occupancy of receptors by ligands – an unappreciated potential biomarker? – George Weiner, Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa
Webinar 2: Translational biomarkers in drug discovery
8th December 2021, 3pm GMT/ 4pm CET/ 10am EST
This webinar will focus on novel translational biomarker discovery and how this is influencing the drug discovery pipeline. It will address the opportunities and challenges in biomarker research and how this is being translated into drug development pipelines.
Speakers:
Applying Big-Data and Mathematical Modeling to Biomarker Discovery – Parag Mallick, Associate Professor, Stanford University
Multi-omic biomarkers for cancer drug response prediction – Altuna Akalin, Group Leader, Head of Bioinformatics & Omics Data Science Platform, Max Delbrück Center
Webinar 3: Novel cancer diagnostics and opportunities
15th December 2021, 3pm GMT/ 4pm CET/ 10am EST
As one of the biggest killer’s, a lot of effort has gone into developing and understanding cancer biomarkers. From early diagnosis to treatment monitoring, this webinar will focus on how cancer biomarkers are influencing our understanding of cancer, and how this can be translated clinically.
Speakers:
Evaluation of disease-perturbed networks in harnessing potential cellular and blood biomarker discovery – Dhiman Ghosh, Scientist II, Takeda
Blood-based molecular biomarkers for differential diagnosis and early detection of pancreatic cancer – Fawaz Al-Shaheri, Ph.D. Student, German Cancer Research Center (DKFZ)
Use of circulating HPV as a biomarker for early detection of patients with cervical cancer relapse– Emmanuelle Jeannot, Research Scientist, Institut Curie
Register for the webinar series:
Speakers
Christopher Peters, Clinical Senior Lecturer and Consultant Upper GI & General Surgeon, Imperial College London
Xianyin Lai, Senior Research Scientist, Eli Lilly
George Weiner, Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa
Parag Mallick, Associate Professor, Stanford University
Altuna Akalin, Group Leader, Head of Bioinformatics & Omics Data Science Platform, Max Delbrück Center
Dhiman Ghosh, Scientist II, Takeda
Fawaz Al-Shaheri, Ph.D. Student, German Cancer Research Center (DKFZ)
Emmanuelle Jeannot, Research Scientist, Institut Curie
